We read with great interest the recent publication by Hylek et al 1 in which they concluded that the rate of bleeding complications during warfarin therapy was substantially higher than previously reported in elderly patients with atrial fibrillation. They emphasize that published rates of major hemorrhage derived from younger noninception cohorts underestimate the bleeding that occurs in clinical practice, and the higher rate of bleeding in their study is attributable to the higher risk of bleeding in the early phase of warfarin therapy and the advanced age of their study subjects. However, the results are not necessarily generalizable to other clinical settings, because the patients enrolled in this cohort have more risk factors for bleeding than representative patients receiving warfarin in clinical practice.
